DOCSLIB.ORG

Endocrinology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Endocrinology Endocrinology Found in most species of the animal kingdom, the endocrine system consists of glands that secrete hormones, and receptors that detect and react to the hormones. In response to environmental stimuli, the endocrine system secretes hormones and uses them as chemical messengers to orchestrate physiological, developmental and reproductive changes that affect the entire body for a long period of time. In order to maintain the proper functioning of the body through its entire life cycle, the endocrine system utilizes a complex feedback mechanism to fine-tune the balance of hormones in the bloodstream. Even a slight disruption to endocrine system’s function can throw off the delicate balance of hormones in the human body and lead to an endocrine disorder, or endocrine disease, such as diabetes, adrenal insufficiency, hyper- or hypothyroidism, and polycystic ovary syndrome (PCOS). www.MedChemExpress.com 1 Endocrinology Inhibitors & Modulators (+)-Cloprostenol (+)-Penbutolol (D-Cloprostenol) Cat. No.: HY-107381 ((R)-Penbutolol; (+)-Isopenbutolol) Cat. No.: HY-116790A (+)-Cloprostenol is a prostaglandin F2α (PGF2α) (+)-Penbutolol is a β-adrenoceptor antagonist, analogue, and shows selective agonistic activity with an IC50 of 0.74 μM. (+)-Penbutolol is an at the prostaglandin receptor. optical isomer of l-penbutolol with Na+ channel-blocking action. Purity: 99.13% Purity: >95.0% Clinical Data: No Development Reported Clinical Data: Launched Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg (+)-Phenserine (-)-Curine Cat. No.: HY-16009 Cat. No.: HY-N2569 (+)-Phenserine is a novel selective cholinesterase (-)-Curine is an orally active noncompetitive inhibitor with an IC50 of 45.3 μM. bisbenzylisoquinoline alkaloid isolated from Chondrodendron platyphyllum. (-)-Curine presents anti-inflammatory and analgesic effects at nontoxic doses, at least in part, resulting from the inhibition of prostaglandin E2 production. Purity: 98.09% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg Size: 1 mg, 5 mg (20S)-Protopanaxatriol (4E)-SUN9221 (20(S)-APPT; g-PPT) Cat. No.: HY-N0835 Cat. No.: HY-U00367 (20S)-Protopanaxatriol is a metabolite of (4E)-SUN9221 is a potent antagonist of ginsenoside, works through the glucocorticoid α1-adrenergic receptor and 5-HT2 receptor, with receptor (GR) and oestrogen receptor (ER), and antihypertensive and anti-platelet aggregation is also a LXRα inhibitor. activities. Purity: >98.0% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 1 mg, 5 mg (9Z,​11E)​-​Prodlure ((9Z,11E)-Tetradecadien-1-yl acetate; (R)-Elagolix Ferodin SL; Litlure A) Cat. No.: HY-101735 (NBI-56418) Cat. No.: HY-14789 (9Z,​11E)​-​Prodlure ((9Z,11E)-Tetradecadien-1-yl Elagolix is a highly potent, selective, acetate) is the main component of the sex orally-active, short-duration, non-peptide pheromone of female Spodoptera littoralis. antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM). Purity: >98.0% Purity: 98.06% Clinical Data: No Development Reported Clinical Data: Phase 3 Size: 10 mM × 1 mL, 10 mg, 50 mg Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg (R)-Propranolol hydrochloride (R)-Terazosin Cat. No.: HY-A0295 Cat. No.: HY-B0371B (R)-Propranolol hydrochloride is a less active (R)-Terazosin is an active R-enantiomer of enantiomer of the β-adrenoceptor Terazosin. (R)-Terazosin is a potent antagonist propranolol (HY-B0573). α1-adrenoceptor antagonist with Ki values of 6.51 nM, 1.01 nM and 1.97 nM for α1a, α1b and α1d-adrenoceptor, respectively. Purity: >98% Purity: 99.77% Clinical Data: Launched Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] (Rac)-Rotigotine hydrochloride (S)-Mapracorat Cat. No.: HY-15394 ((S)-ZK-245186; (S)-BOL-303242X) Cat. No.: HY-14864A (Rac)-Rotigotine hydrochloride is a racemate of (S)-Mapracorat is a selective and less active Rotigotine. glucocorticoid receptor agonist. Purity: 97.76% Purity: 99.40% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg Size: 5 mg, 10 mg (S)-Terazosin (±)-Befunolol Cat. No.: HY-B0371D Cat. No.: HY-101752 (S)-Terazosin is an active S-enantiomer of (±)-Befunolol is a β-adrenoceptor blocking agent. Terazosin. (S)-Terazosin is a potent and high-affinity α-adrenoceptor antagonist with Ki values of 3.91 nM, 0.79 nM and 1.16 nM for α1a, α1b and α1d-adrenoceptor, respectively. Purity: 99.77% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 1 mg, 5 mg (±)-Bisoprolol hemifumarate (±)-Methotrimeprazine (D6) (Bisoprolol hemifumarate salt) Cat. No.: HY-B0076 (dl-Methotrimeprazine D6) Cat. No.: HY-19489S (±)-Bisoprolol (hemifumarate) is a selective type (±)-Methotrimeprazine (D6) is the deuterium β1 adrenergic receptor blocker. Target: Adrenergic labeled Methotrimeprazine, which is a D3 dopamine Receptor Approved: July 31, 1992 Bisoprolol, on and Histamine H1 receptor antagonist. beta 1-adrenoceptor peptide induced autoimmune myocardial damage. Purity: 99.65% Purity: >98.0% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg Size: 1 mg (±)-Tazifylline 11-Beta-hydroxyandrostenedione Cat. No.: HY-U00018 (4-Androsten-11β-ol-3,17-dione) Cat. No.: HY-114464 (±)-Tazifylline is a potent, selective and 11-Beta-hydroxyandrostenedione long-acting histamine H1 receptor antagonist. (4-Androsten-11β-ol-3,17-dione) is a steroid mainly found in the the adrenal origin (11β-hydroxylase is present in adrenal tissue, but absent in ovarian tissue). Purity: >98% Purity: >98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg 11-Ketodihydrotestosterone 11-Oxo etiocholanolone (11-KDHT; 5α-Dihydro-11-keto testosterone) Cat. No.: HY-135794 (11-Ketoetiocholanolone) Cat. No.: HY-113457 11-Ketodihydrotestosterone (11-KDHT; 11-Oxo etiocholanolone (11-Ketoetiocholanolone) is 5α-Dihydro-11-keto testosterone) is an endogenous a metabolite of Etiocholanolone. Etiocholanolone steroid and a metabolite of is the excreted metabolite of testosterone and has 11β-Hydroxyandrostenedione. anticonvulsant activity. Purity: 98.65% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg Size: 1 mg, 5 mg www.MedChemExpress.com 3 11β-Hydroxyandrosterone 16-​Dehydroprogesterone Cat. No.: HY-113351 Cat. No.: HY-128378 11β-Hydroxyandrosterone is a 11-oxygenated 16-Dehydroprogesterone is a steroidal progestin. androgen metabolite of 11β-hydroxyandrostenedione. Purity: >98.0% Purity: 99.53% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg Size: 10 mM × 1 mL, 50 mg 17a-Hydroxypregnenolone 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide Cat. No.: HY-113263 Cat. No.: HY-100287 17a-Hydroxypregnenolone is a pregnane steroid. 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) 17a-Hydroxypregnenolone is a prohormone in the sulfide is a compound that inhibits stress-induced formation of dehydroepiandrosterone (DHEA). ulcer and low toxicity, and can maintain the content of phospholipase A2 and prostaglandin E2 in ulcerated rats induced by water immersed restrained stress. Purity: 98.06% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 50 mg, 100 mg Size: 1 mg, 5 mg 2-Selenouracil 2-Thiouracil Cat. No.: HY-111959 (Thiouracil) Cat. No.: HY-B0503 2-Selenouracil is a useful specialized 2-Thiouracil (Thiouracil) is an antithyroid photosensitizer for photodynamical therapy. compound. 2-Thiouracil can function as a highly specific melanoma seeker. 2-Thiouracil is a selective inhibitor of neuronal nitric oxide synthase (nNOS) with a Ki of 20 μM. Purity: >98% Purity: >99.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 500 mg 3,4-Dimethoxyphenol 3,5-Diiodothyropropionic acid Cat. No.: HY-N1780 Cat. No.: HY-126236 3,4-Dimethoxyphenol is a plant-derived 3,5-Diiodothyropropionic acid is a thyroid hormone phenylpropanoid compound and can use as a analog, induces α-myosin heavy chain mRNA whitening agent in cosmetics. 3,4-Dimethoxyphenol expression, binds to thyroid hormone receptor -1 has tyrosinase-inhibiting activity. (TR), with Ka of 2.40 and 4.06 M for TRα1 3,4-Dimethoxyphenol has potent antioxidant effect and TRβ1, respectively. isolated from the bacterial fermentation broth. Purity: 99.51% Purity: 98.94% Clinical Data: No Development Reported Clinical Data: Size: 10 mM × 1 mL, 100 mg Size: 5 mg, 10 mg 3-Keto petromyzonol 31-Norlanostenol Cat. No.: HY-119332 Cat. No.: HY-N7267 3-Keto petromyzonol, a main component of Sea 31-Norlanostenol is a triterpenic compound lamprey male sex pheromones, modulates both isolated from the latex of Euphorbia synthesis and release of gonadotropin releasing officinarum. 31-Norlanostenol can act as hormone (GnRH), and subsequently, efficient insect growth regulator on S. frugiperda hypothalamic-pituitary-gonadal (HPG) output in and Tenebrio molitor. immature sea lamprey. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg 4 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] 4(3H)-Quinazolinone 4,4'-Iminodiphenol Cat. No.: HY-W018800 Cat. No.: HY-135324 4(3H)-Quinazolinone is a building block in 4-Propionamidophenol (compound 4a) is an inactive chemical synthesis. Biologically active nitrogen estrogen receptor ligand based on the heterocyclic compounds. Possesses a wide spectrum diphenylamine skeleton. of biological properties like antibacterial, antifungal, anticonvulsant, anti-inflammatory, anti-HIV, anticancerous and analgesic activities.
Load more

Recommended publications
  • DHEA | Medchemexpress
    Inhibitors Product Data Sheet DHEA • Agonists Cat. No.: HY-14650 CAS No.: 53-43-0 Molecular Formula: C₁₉H₂₈O₂ • Molecular Weight: 288.42 Screening Libraries Target: Androgen Receptor; Endogenous Metabolite Pathway: Others; Metabolic Enzyme/Protease Storage: Please store the product under the recommended conditions in the Certificate of Analysis. SOLVENT & SOLUBILITY In Vitro DMSO : 50 mg/mL (173.36 mM; Need ultrasonic) Ethanol : 50 mg/mL (173.36 mM; Need ultrasonic) H2O : 1 mg/mL (3.47 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 3.4672 mL 17.3358 mL 34.6717 mL Stock Solutions 5 mM 0.6934 mL 3.4672 mL 6.9343 mL 10 mM 0.3467 mL 1.7336 mL 3.4672 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: Cremophor EL Solubility: 14.29 mg/mL (49.55 mM); Clear solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution 5. Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution 6.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Development of Psychophysiological Motoric Reactivity Is Influenced By
    Development of psychophysiological motoric reactivity is influenced by peripubertal pharmacological inhibition of gonadotropin releasing hormone action - Results of an ovine model Neil P. Evans, Jane Robinson J.E., Hans Erhard, Erik Ropstad, Lynne M. Fleming, Ira Ronit Hebold Haraldsen To cite this version: Neil P. Evans, Jane Robinson J.E., Hans Erhard, Erik Ropstad, Lynne M. Fleming, et al.. Develop- ment of psychophysiological motoric reactivity is influenced by peripubertal pharmacological inhibition of gonadotropin releasing hormone action - Results of an ovine model. Psychoneuroendocrinology, El- sevier, 2012, 37 (11), pp.1876-1884. 10.1016/j.psyneuen.2012.03.020. hal-01186791 HAL Id: hal-01186791 https://hal.archives-ouvertes.fr/hal-01186791 Submitted on 29 May 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. + Models PNEC-2163; No. of Pages 9 Psychoneuroendocrinology (2012) xxx, xxx—xxx Available online at www.sciencedirect.com j ournal homepage: www.elsevier.com/locate/psyneuen Development of psychophysiological motoric reactivity is influenced by peripubertal pharmacological inhibition of gonadotropin releasing § hormone action — Results of an ovine model a, a b c Neil P. Evans *, Jane E. Robinson , Hans W. Erhard , Erik Ropstad , a d Lynne M.
    [Show full text]
  • Effect of Vitamin C on Bisphenol a Induced Hepato& Nephrotoxicity in Albino Rats
    Haroun et al. 57 EFFECT OF VITAMIN C ON BISPHENOL A INDUCED HEPATO& NEPHROTOXICITY IN ALBINO RATS Marcelle R. Haroun,M.D.*, Ibrahim S. Zamzam, M.D.*,Eslam S. Metwally, M.D.*, and Rabab Sh. EL-Shafey, M.S.C. * *Forensic Medicine & Clinical Toxicology Department, Faculty of Medicine, Benha University, Egypt [email protected] [email protected] [email protected] [email protected] ABSTRACT Bisphenol-A (BPA) is a worldwide used endocrine disruptor that is incorporated in many plastic industries. The exposure of humans to that substance starts early during the fetal life. Many agencies raised warnings against the excessive use of such substances. The present study aimed to evaluate the oxidative stress effect of BPA on liver and kidney of albino rats, and whether co-administration of vitamin C can ameliorate this oxidative damage. Albino rats were divided into six groups: -ve control group,+ve control group,vitamin C (60mglkg) treated group, BPA treated group, BPA+ high dose of vitamin C (60mglkg) treated group, and BPA+ low dose of vitamin C (5.5mglkg) treated group The oxidative stress arising from BPA was evaluated in liver and kidney tissues. In addition, serum creatinine, uric acid levels, (AST) and (ALT) activities as markers of kidney and liver function were measured. Biochemical analysis revealed significant reduction in activities of enzymatic antioxidants in BPA treated group and BPA + vitamin C treated groups in high & low doses as compared to control group. In addition, there were significant increase in AST, ALT, uric acid, and creatinine levels in BPA treated group and reduction in their concentrations BPA + vitamin C treated groups in high & low doses as compared to control group.
    [Show full text]
  • III IIII USO05721278A United States Patent (19) 11) Patent Number: 5,721,278 Garfield Et Al
    III IIII USO05721278A United States Patent (19) 11) Patent Number: 5,721,278 Garfield et al. 45) Date of Patent: Feb. 24, 1998 54 OWULATON CONTROL BY REGULATING 58) Field of Search ............................ 514/15, 121, 651, NTRC OXDE LEVELS 514/652,561, 841, 843, 648 Inventors: Robert E. Garfield, Friendswood; 56 References Cited Chandrasekhar Yallampalli, Houston, U.S. PATENT DOCUMENTS both of Tex. 4,338,305 7/1982 Corbin ................................... 424/177 73 Assignee: Board of Regents, The University of 4,851,385 7/1989 Rueske ..................................... 514/15 Texas System, Austin,Tex. 5,470,847 11/1995 Garfield et al. ......................... 514/171. Primary Examiner. Theodore J. Criares 21 Appl. No.: 477,187 Attorney, Agent, or Firm-Arnold, White & Durkee 22 Filed: Jun. 7, 1995 57 ABSTRACT Inhibition of ovulation in a female may be achieved by Related U.S. Application Data administering a nitric oxide synthase inhibitor, alone or in 62 Division of Ser. No. 165,309, Dec. 10, 1993, Pat. No. combination with one or more of a progestin, an estrogen, 5,470,847. and an LH-RH antagonist, thereby preventing conception. The stimulation of ovulation in a female may be achieved by 51) Int. Cl. ......... A61K 31/195; A61K 31/135: administering a nitric oxide source, optionally in further A61K 31/56 combination with one or more of clomiphene, a 52 U.S.C. ....................... 514/652; 514/171; 514/561; gonadotropin, and an LH-RH agonist. 514/563; 514/651; 514/565; 514/841; 514/843; 514/648 4 Claims, 1 Drawing Sheet U.S. Patent Feb. 24, 1998 5,721,278 HypothalamuS Anterior Pituitary Gland ProgesterOne Estrogen / \ CorpOra OVa lutea \(es j \s 63 O Graafian follicle Follicular Ovulatory Luteal PaSe Phase Phase FIG.
    [Show full text]
  • Campro Catalog Stable Isotope
    Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information ..............................................................................................
    [Show full text]
  • Pesticides Reduce Symbiotic Efficiency of Nitrogen-Fixing Rhizobia and Host Plants
    Pesticides reduce symbiotic efficiency of nitrogen-fixing rhizobia and host plants Jennifer E. Fox*†, Jay Gulledge‡, Erika Engelhaupt§, Matthew E. Burow†¶, and John A. McLachlan†ʈ *Center for Ecology and Evolutionary Biology, University of Oregon, 335 Pacific Hall, Eugene, OR 97403; †Center for Bioenvironmental Research, Environmental Endocrinology Laboratory, Tulane University, 1430 Tulane Avenue, New Orleans, LA 70112-2699; ‡Department of Biology, University of Louisville, Louisville, KY 40292 ; §University of Colorado, Boulder, CO 80309; and ¶Department of Medicine and Surgery, Hematology and Medical Oncology Section, Tulane University Medical School, 1430 Tulane Avenue, New Orleans, LA 70112-2699 Edited by Christopher B. Field, Carnegie Institution of Washington, Stanford, CA, and approved May 8, 2007 (received for review January 8, 2007) Unprecedented agricultural intensification and increased crop by plants, in rotation with non-N-fixing crops (8, 15). The yield will be necessary to feed the burgeoning world population, effectiveness of this strategy relies on maximizing symbiotic N whose global food demand is projected to double in the next 50 fixation (SNF) and plant yield to resupply organic and inorganic years. Although grain production has doubled in the past four N and nutrients to the soil. The vast majority of biologically fixed decades, largely because of the widespread use of synthetic N is attributable to symbioses between leguminous plants (soy- nitrogenous fertilizers, pesticides, and irrigation promoted by the bean, alfalfa, etc.) and species of Rhizobium bacteria; replacing ‘‘Green Revolution,’’ this rate of increased agricultural output is this natural fertilizer source with synthetic N fertilizer would cost unsustainable because of declining crop yields and environmental Ϸ$10 billion annually (16, 17).
    [Show full text]
  • 204569Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204569Orig1s000 MEDICAL REVIEW(S) Cross Discipline Team Leader Review 3. CMC/Device Dr. Khairuzzaman found the drug product portion of the NDA to be acceptable, and without need for phase 4 commitments. Dr. Sapru’s review stated that with the exception of a pending issue concerning the control of potential genotoxic impurity (b) (4) the NDA was approvable in terms of drug substance. Dr. Suarez found that the NDA was acceptable from a biopharmaceutics perspective. The Office of Compliance issuance of an acceptable recommendation for drug substance manufacturing and testing facilities was pending at the time of this review. 4. Nonclinical Pharmacology/Toxicology Dr. Richard Siarey completed the primary nonclinical review, and Dr. Lois Freed completed a supervisory memo. Dr. Siarey’s overall conclusion was that from a nonclinical perspective, approval of the suvorexant NDA was recommended. However, he found evidence that catapelxy was observed in dogs exposed to MK-4305 (suvorexant) near Tmax, although he concluded that additional information could have been gained by studying the drug in an experimental model that has been used for diagnosing cataplexy in dogs. Dr. Siarey suggested that since cataplexy occurred in dogs near Tmax, a time at which if used for insomnia patients would ordinarily be in bed, safety concern for humans was reduced. Dr. Siarey also found that the neurobehavioral assessment in the pre- and post-natal developmental study was not complete, as the passive avoidance tests was performed too early in development, while learning/acquisition tests and retention/memory tests were not conducted.
    [Show full text]
  • Anti-Infectives Industry Over the Next 5 Years and Beyond
    Bridging the innovation gap... New Drug Futures: Products that could change the pharma market to 2013 and beyond Over 70 pipeline prospects This new major and insightful 450 page in 8 major therapy areas analysis evaluates, compares and contrasts the are analysed in this report prospects for the development compounds that could revolutionise the pharmaceutical Anti-infectives industry over the next 5 years and beyond. Cardiovascular CNS The report provides: Gastrointestinal Detailed background and market context for Metabolic each therapy area covered: Musculoskeletal Addressable patient population Oncology Current treatments Sales drivers Respiratory Sales breakers Future treatments Market dynamics – winners and losers Key drug launches by 2013 Unique sales forecasts by major product to 2013 Over 70 key products assessed Unique evaluation scores for key areas such as novelty of mechanism, clinical data and competition Critical and detailed appraisal of each product‟s research and development Extensive pipeline listings, putting the profiled products into their competitive context The search – and need – for new products has never been greater and what’s in the development pipeline has never generated more interest. That is why this analysis is so important! GLOBAL PHARMA MARKET IN CONTEXT THE Are there too many prophets of doom ready to write-off the research-based pharma industry in the future? Too few novel There is plenty on which to base such anxiety. The research-based industry products and an must achieve a fair price in the face of greater cost control, while the aggressive generic burden of regulation is setting the bar high for successful product sector are taking introduction.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Premenstrual Syndrome: a Natural Approach to Management
    CNI506 8/99 Vol. 5, No. 6 APPLIED NUTRITIONAL SCIENCE REPORTS Copyright © 1997 Advanced Nutrition Publications, Inc. rev. 1999 Premenstrual Syndrome: A Natural Approach to Management BY JOSEPH L. MAYO, MD, FACOG ABSTRACT: Premenstrual syndrome (PMS) is a disorder that imbalances, nutritional insufficiencies, and psychologic factors. occurs during the luteal phase of the menstrual cycle, producing A nutritional approach to PMS that takes into account the complex a diverse number of physical and emotional changes. The most interactions of all bodily systems that influence hormonal balance common symptoms of PMS include bloating, backache, breast and neuroendocrine function, with an emphasis on the liver, is tenderness, food cravings, fatigue, irritability, and depression. recommended. The nutritional factors that have been studied The timing of the appearance and disappearance of symptoms, include vitamin B6, magnesium, zinc, choline, vitamin E, and rather than the presence of specific symptoms, is of more essential fatty acids, in addition to weight management and importance in the diagnosis of PMS. The direct cause of PMS is stress reduction. Herbal therapies have also proven beneficial in unknown, although there are numerous theories relating to hormonal the management of PMS. PREMENSTRUAL SYNDROME symptoms such as bloating, breast tenderness, and headache (Table 1).3-5 These diverse symptoms may range from mild Cyclic symptoms in women of reproductive age have been to incapacitating. In some women a single symptom, such recognized for thousands of years. First appearing in the medical as depression, may predominate, whereas others may have literature in 1931 and originally termed “premenstrual tension,” several symptoms.1 this condition has been renamed “premenstrual syndrome” (PMS) in an effort to take into account the different clinical Table.
    [Show full text]
  • Pharmaceuticals and Endocrine Active Chemicals in Minnesota Lakes
    Pharmaceuticals and Endocrine Active Chemicals in Minnesota Lakes May 2013 Authors Mark Ferrey Contributors/acknowledgements The MPCA is reducing printing and mailing costs This report contains the results of a study that by using the Internet to distribute reports and characterizes the presence of unregulated information to wider audience. Visit our website contaminants in Minnesota’s lakes. The study for more information. was made possible through funding by the MPCA reports are printed on 100 percent post- Minnesota Clean Water Fund and by funding by consumer recycled content paper manufactured the U.S. Environmental Protection Agency without chlorine or chlorine derivatives. (EPA), which facilitated the sampling of lakes for this study. The Minnesota Pollution Control Agency (MPCA) thanks the following for assistance and advice in designing and carrying out this study: Steve Heiskary, Pam Anderson, Dereck Richter, Lee Engel, Amy Garcia, Will Long, Jesse Anderson, Ben Larson, and Kelly O’Hara for the long hours of sampling for this study. Cynthia Tomey, Kirsten Anderson, and Richard Grace of Axys Analytical Labs for the expert help in developing the list of analytes for this study and logistics to make it a success. Minnesota Pollution Control Agency 520 Lafayette Road North | Saint Paul, MN 55155-4194 | www.pca.state.mn.us | 651-296-6300 Toll free 800-657-3864 | TTY 651-282-5332 This report is available in alternative formats upon request, and online at www.pca.state.mn.us. Document number: tdr-g1-16 Contents Contents ...........................................................................................................................................
    [Show full text]